Defining response and remission in anxiety disorders: Toward an integrated approach

CNS Spectrums

Volumn 11, Issue SUPPL. 12, 2006, Pages 21-28

  Bandelow, Borwin ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DRUG EFFICACY; FUNCTIONAL DISEASE; GENERALIZED ANXIETY DISORDER; HUMAN; MEASUREMENT; PANIC; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; REMISSION; SOCIAL PHOBIA; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

EID: 33750283860     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900025815     Document Type: Article

References (33)

1. ECDEU Assessment Manual for Psychopharmacology. rev. Guy W, ed. (1976) National Institute of Mental Health, Psychopharmacology Research Branch: Rockville, MD; 1976.
2. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
3. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141-173.
4. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol. 1995;10:73-81.
5. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154:1571-1575.
6. European Medicines Agency Committee for Medical Products for Human Use: Guideline on clinical investigation of medical products indicated for the treatment of panic disorder. Available at: http://www.emea.eu.int/pdfs/human/ ewp/428002. en.pdf. Accessed August 17, 2006.
7. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407-415.
8. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81-87.
9. Furukawa TA, Jaeschke R, Cook D, Guyatt G. Measurements of Patients' Discomfort. Distress and Disability: Users' Guide to the Medical Literature. Chicago, IL: American Medical Association Press; 2006.
10. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12-19.
11. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(suppl 22):29-34.
12. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003;64(suppl 15):40-45.
13. Pollack MH, Meoni P, Otto MW, Hackett D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003;23:250-259.
14. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:749-756.
15. Zimmerman M, Posternak MA, Chelminski I. Is the cutoff to define remission on the Hamilton Rating Scale for Depression too high? J Nerv Ment Dis. 2005;193:170-175.
16. Allgulander C, Hackett D, Saunas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15-22.
17. Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60:528-535.
18. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Saunas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000;283:3082-3088.
19. Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry. 2003;18:182-187.
20. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968-974.
21. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004;19:387-396.
22. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine vs paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62:190-198.
23. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005;66:238-247.
24. Rickels K, Mangano R, Khan A. Double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24(5):488-496.
25. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:352-359.
26. Liebowitz MR, Asnis G, Tzanis E, Whitaker T. Venlafaxine XR versus placebo in the short-term treatment of panic disorder. Poster presented at: Annual Meeting of the American Psychiatric Association; May 1-6, 2004: New York, NY.
27. Pollack M, Mangano RM, Entsuah R, Tzanis E. Short-term treatment of panic disorder: venlafaxine XR vs paroxetine or placebo. Poster presented at: American Psychiatric Association Annual Meeting; May 21-26, 2005; Atlanta, GA.
28. Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2006 August 7; [Epub ahead of prin t]
29. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001;62(suppl 12):5-9.
30. Sheehan DV. The Anxiety Disease. New York, NY: Charles Scribners Sons; 1983.
31. Bandelow B, Andersen HF, Dolberg OT. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety. 2006. In press.
32. Shear MK, Clark D, Feske U. The road to recovery in panic disorder: response, remission, and relapse. J Clin Psychiatry. 1998;59(suppl 8):4-8.
33. Shear K, Belnap BH, Mazumdar S, Houck P, Rollman BL. Generalized anxiety disorder severity scale (GADSS): a preliminary validation study. Depress Anxiety. 2006;23:77-82.